Literature DB >> 18177457

IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease.

Shinichiro Shinzaki1, Hideki Iijima, Takatoshi Nakagawa, Satoshi Egawa, Sachiko Nakajima, Shuji Ishii, Takanobu Irie, Yoshimi Kakiuchi, Tsutomu Nishida, Masakazu Yasumaru, Tatsuya Kanto, Masahiko Tsujii, Shingo Tsuji, Tsunekazu Mizushima, Harumasa Yoshihara, Akihiro Kondo, Eiji Miyoshi, Norio Hayashi.   

Abstract

BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) share several immunologic similarities with rheumatoid arthritis (RA). Patients with RA have significantly increased levels of serum agalactosyl immunoglobulin G (IgG). Our aim was to investigate the clinical significance of analyzing the oligosaccharide structure of serum IgG in patients with IBD.
METHODS: Serum IgG oligosaccharide structures were analyzed using high-performance liquid chromatography in 60 patients with Crohn's disease (CD), 58 patients with ulcerative colitis (UC), 27 healthy volunteers (HV), and 15 disease controls (DC). The activity and mRNA level of beta-1,4-galactosyltransferase (Beta4GalT) in antibody-secreting cells were investigated in these subjects.
RESULTS: The agalactosyl fraction of the fucosylated IgG oligosaccharides (G0F/G2F) in CD and UC was significantly greater than that in HV and DC (P < 0.001). The percentage of subjects with a high G0F/G2F in CD, UC, HV, and DC was 72%, 33%, 0%, and 0%, respectively. G0F/G2F, which is significantly correlated with disease severity in both CD and UC, had higher sensitivity to diagnose IBD compared with anti-Saccharomyces cerevisiae antibody. Moreover, G0F/G2F was significantly correlated with the prognosis of UC patients: patients with a high G0F/G2F did not maintain long-term remission. The activity and mRNA level of Beta4GalT were significantly elevated in UC but not in CD.
CONCLUSIONS: G0F/G2F is a potentially effective diagnostic marker of disease activity in both CD and UC, and of the clinical course in UC. A pathophysiologic difference between CD and UC was also demonstrated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177457     DOI: 10.1111/j.1572-0241.2007.01699.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  29 in total

Review 1.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 2.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

3.  Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.

Authors:  I Schwab; F Nimmerjahn
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 4.  Type I and type II Fc receptors regulate innate and adaptive immunity.

Authors:  Andrew Pincetic; Stylianos Bournazos; David J DiLillo; Jad Maamary; Taia T Wang; Rony Dahan; Benjamin-Maximillian Fiebiger; Jeffrey V Ravetch
Journal:  Nat Immunol       Date:  2014-08       Impact factor: 25.606

5.  Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases.

Authors:  Mirna Šimurina; Noortje de Haan; Frano Vučković; Nicholas A Kennedy; Jerko Štambuk; David Falck; Irena Trbojević-Akmačić; Florent Clerc; Genadij Razdorov; Anna Khon; Anna Latiano; Renata D'Incà; Silvio Danese; Stephan Targan; Carol Landers; Marla Dubinsky; Dermot P B McGovern; Vito Annese; Manfred Wuhrer; Gordan Lauc
Journal:  Gastroenterology       Date:  2018-01-06       Impact factor: 22.682

Review 6.  Diagnosis of inflammatory bowel disease: Potential role of molecular biometrics.

Authors:  Amosy E M'Koma
Journal:  World J Gastrointest Surg       Date:  2014-11-27

7.  Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.

Authors:  Erin H Seeley; Mary K Washington; Richard M Caprioli; Amosy E M'Koma
Journal:  Proteomics Clin Appl       Date:  2013-05-08       Impact factor: 3.494

8.  N-Acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis.

Authors:  Shinichiro Shinzaki; Mayuko Ishii; Hironobu Fujii; Hideki Iijima; Kana Wakamatsu; Shoichiro Kawai; Eri Shiraishi; Satoshi Hiyama; Takahiro Inoue; Yoshito Hayashi; Ryusuke Kuwahara; Shinji Takamatsu; Yoshihiro Kamada; Eiichi Morii; Masahiko Tsujii; Tetsuo Takehara; Eiji Miyoshi
Journal:  J Gastroenterol       Date:  2015-09-08       Impact factor: 7.527

9.  Lectin-reactive anti-α-gal in patients with Crohn's disease: correlation with clinical phenotypes.

Authors:  Parham Safaie; Maggie Ham; Peter Kuang; Anand S Mehta; Mengjun Wang; Adam S Cheifetz; Simon Robson; Daryl Lau; Timothy M Block; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

10.  Twin studies on the effect of genetic factors on serum agalactosyl immunoglobulin G levels.

Authors:  Kanako Azuma; Shinichiro Shinzaki; Hitomi Asazawa; Eri Kuroki; Sayuri Kawamoto; Yoshihiro Kamada; Kazuo Hayakawa; Eiji Miyoshi
Journal:  Biomed Rep       Date:  2014-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.